{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T23:11:51Z","timestamp":1793661111165,"version":"4.5.1"},"reference-count":54,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,2,12]],"date-time":"2026-02-12T00:00:00Z","timestamp":1770854400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Revue Neurologique"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1016\/j.neurol.2026.01.267","type":"journal-article","created":{"date-parts":[[2026,2,23]],"date-time":"2026-02-23T12:28:41Z","timestamp":1771849721000},"page":"270-279","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Simulated shared and supported decision making for amyloid immunotherapy in Alzheimer's disease: A bicentric study"],"prefix":"10.1016","volume":"182","author":[{"given":"E.","family":"Burry","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-7335-2129","authenticated-orcid":false,"given":"F.","family":"Plumacker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7429-4289","authenticated-orcid":false,"given":"N.","family":"Villain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Amaral","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3869-0564","authenticated-orcid":false,"given":"P.","family":"Damier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Delrieu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.-A.","family":"Mackowiak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Michalon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Mohr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V.","family":"Planche","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Rollin-Sillaire","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3476-9822","authenticated-orcid":false,"given":"T.","family":"Tannou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Wallon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Desmoulin Canselier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4386-6045","authenticated-orcid":false,"given":"T.","family":"Lebouvier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Fran\u00e7ois","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.neurol.2026.01.267_bib0275","series-title":"FDA converts novel Alzheimer's disease treatment to traditional approval","year":"2023"},{"key":"10.1016\/j.neurol.2026.01.267_bib0280","series-title":"Approval of the marketing authorisation for Leqembi (lecanemab)","year":"2024"},{"key":"10.1016\/j.neurol.2026.01.267_bib0285","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/s13195-016-0181-2","article-title":"Safety and tolerability of BAN2401 - a clinical study in Alzheimer's disease with a protofibril selective A\u03b2 antibody","volume":"8","author":"Logovinsky","year":"2016","journal-title":"Alzheimer Res Ther"},{"key":"10.1016\/j.neurol.2026.01.267_bib0290","article-title":"Lecanemab in Early Alzheimer's disease","author":"Dyck","year":"2022","journal-title":"New Engl J Med"},{"key":"10.1016\/j.neurol.2026.01.267_bib0295","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1186\/s13195-021-00813-8","article-title":"A randomized, double-blind, phase 2b proof-of-concept clinical trial in early Alzheimer's disease with lecanemab, an anti-A\u03b2 protofibril antibody","volume":"13","author":"Swanson","year":"2021","journal-title":"Alzheimer Res Ther"},{"key":"10.1016\/j.neurol.2026.01.267_bib0300","doi-asserted-by":"crossref","first-page":"e70081","DOI":"10.1002\/trc2.70081","article-title":"Measuring time saved in Alzheimer's disease: what is a meaningful slowing of progression?","volume":"11","author":"Lanctot","year":"2025","journal-title":"Alzheimer Dement: Transl Res Clin Interv"},{"key":"10.1016\/j.neurol.2026.01.267_bib0305","doi-asserted-by":"crossref","first-page":"771","DOI":"10.14283\/jpad.2023.123","article-title":"Lecanemab Clarity AD: quality-of-life results from a randomized, double-blind phase 3 trial in Early Alzheimer's disease","volume":"10","author":"Cohen","year":"2023","journal-title":"J Prev Alzheimer's Dis"},{"issue":"7","key":"10.1016\/j.neurol.2026.01.267_bib0310","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1001\/jamaneurol.2023.0815","article-title":"Advocating for demonstration of disease modification\u2014have we been approaching clinical trials in early Alzheimer disease incorrectly?","volume":"80","author":"Planche","year":"2023","journal-title":"JAMA Neurol"},{"key":"10.1016\/j.neurol.2026.01.267_bib0315","doi-asserted-by":"crossref","first-page":"2730","DOI":"10.1002\/alz.12959","article-title":"Expectations and clinical meaningfulness of randomized controlled trials","volume":"19","author":"Petersen","year":"2023","journal-title":"Alzheimer Dement"},{"key":"10.1016\/j.neurol.2026.01.267_bib0320","doi-asserted-by":"crossref","DOI":"10.1093\/braincomms\/fcad175","article-title":"Key questions for the evaluation of anti-amyloid immunotherapies for Alzheimer's disease","volume":"5","author":"Liu","year":"2023","journal-title":"Brain Commun"},{"key":"10.1016\/j.neurol.2026.01.267_bib0325","doi-asserted-by":"crossref","first-page":"6659","DOI":"10.1002\/alz.14114","article-title":"Are lecanemab and donanemab disease-modifying therapies?","volume":"20","author":"Daly","year":"2024","journal-title":"Alzheimer's Dement"},{"key":"10.1016\/j.neurol.2026.01.267_bib0330","doi-asserted-by":"crossref","first-page":"4414","DOI":"10.1093\/brain\/awad188","article-title":"Amyloid-related imaging abnormalities (ARIA): radiological, biological and clinical characteristics","volume":"146","author":"Hampel","year":"2023","journal-title":"Brain"},{"key":"10.1016\/j.neurol.2026.01.267_bib0335","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1186\/s13195-024-01441-8","article-title":"Updated safety results from phase 3 lecanemab study in early Alzheimer's disease","volume":"16","author":"Honig","year":"2024","journal-title":"Alzheimer's Res Ther"},{"key":"10.1016\/j.neurol.2026.01.267_bib0340","series-title":"Leqembi: EPAR public assessment report","year":"2024"},{"key":"10.1016\/j.neurol.2026.01.267_bib0345","doi-asserted-by":"crossref","first-page":"e00570","DOI":"10.1016\/j.neurot.2025.e00570","article-title":"Maximizing the benefit and managing the risk of anti-amyloid monoclonal antibody therapy for Alzheimer's disease: strategies and research directions","volume":"22","author":"Cummings","year":"2025","journal-title":"Neurotherapeutics"},{"key":"10.1016\/j.neurol.2026.01.267_bib0350","series-title":"Patient et professionnels de sant\u00e9: d\u00e9cider ensemble\u2013Concept, aides destin\u00e9es aux patients et impact de la \u00ab\u00a0d\u00e9cision m\u00e9dicale partag\u00e9e\u00a0\u00bb\u00a0: \u00e9tat des lieux","year":"2013"},{"key":"10.1016\/j.neurol.2026.01.267_bib0355","unstructured":"World Health Organization. Integrated people-centred care, https:\/\/www.who.int\/health-topics\/integrated-people-centered-care?utm_source=chatgpt.com#tab=tab_1, 2024 [accessed 2025 Dec 19]."},{"key":"10.1016\/j.neurol.2026.01.267_bib0360","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1017\/S1041610219000516","article-title":"Competency of aMCI patients to consent to cholinesterase treatment","volume":"32","author":"Oshima","year":"2020","journal-title":"Int Psychogeriatr"},{"key":"10.1016\/j.neurol.2026.01.267_bib0365","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1017\/S1041610220004056","article-title":"Decisional capacity to consent to treatment and research in patients affected by Mild Cognitive Impairment. A systematic review and meta-analysis","volume":"34","author":"Parmigiani","year":"2022","journal-title":"Int Psychogeriatr"},{"key":"10.1016\/j.neurol.2026.01.267_bib0370","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1017\/ipm.2017.59","article-title":"Spot the difference: shared decision-making and supported decision-making in mental health","volume":"34","author":"Simmons","year":"2017","journal-title":"Ir J Psychol Med"},{"key":"10.1016\/j.neurol.2026.01.267_bib0375","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1080\/15265161.2020.1863507","article-title":"Supported decision making with people at the margins of autonomy","volume":"21","author":"Peterson","year":"2021","journal-title":"Am J Bioeth"},{"issue":"11","key":"10.1016\/j.neurol.2026.01.267_bib0380","doi-asserted-by":"crossref","first-page":"3566","DOI":"10.1111\/jgs.18596","article-title":"Supported decision making: Facilitating the self-determination of persons living with Alzheimer's and related diseases","volume":"71","author":"Largent","year":"2023","journal-title":"J Am Geriatr Soc"},{"key":"10.1016\/j.neurol.2026.01.267_bib0385","doi-asserted-by":"crossref","first-page":"e32829","DOI":"10.1097\/MD.0000000000032829","article-title":"Use of Delphi in health sciences research: a narrative review","volume":"102","author":"Shang","year":"2023","journal-title":"Medicine"},{"key":"10.1016\/j.neurol.2026.01.267_bib0390","doi-asserted-by":"crossref","first-page":"100094","DOI":"10.1016\/j.tjpad.2025.100094","article-title":"Lecanemab for early Alzheimer's disease: appropriate use recommendations from the French federation of memory clinics","volume":"12","author":"Villain","year":"2025","journal-title":"J Prev Alzheimer Dis"},{"key":"10.1016\/j.neurol.2026.01.267_bib0395","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1111\/j.1532-5415.2007.01499.x","article-title":"Natural history of decline in instrumental activities of daily living performance over the 10 years preceding the clinical diagnosis of dementia: a prospective population-based study","volume":"56","author":"P\u00e9r\u00e8s","year":"2008","journal-title":"J Am Geriatr Soc"},{"key":"10.1016\/j.neurol.2026.01.267_bib0400","first-page":"81","article-title":"Alzheimer disease as a clinical-biological construct\u2013An International Working Group Recommendation","author":"Dubois","year":"2024","journal-title":"JAMA Neurol"},{"key":"10.1016\/j.neurol.2026.01.267_bib0405","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1016\/S1474-4422(21)00066-1","article-title":"Clinical diagnosis of Alzheimer's disease: recommendations of the International Working Group","volume":"20","author":"Dubois","year":"2021","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.neurol.2026.01.267_bib0410","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/0022-3956(75)90026-6","article-title":"\u201cMini-mental state\u201d. A practical method for grading the cognitive state of patients for the clinician","volume":"12","author":"Folstein","year":"1975","journal-title":"J Psychiatr Res"},{"key":"10.1016\/j.neurol.2026.01.267_bib0415","series-title":"International Standard Classification of Education: ISCED 2011","year":"2012"},{"key":"10.1016\/j.neurol.2026.01.267_bib0420","unstructured":"Institut national de la statistique et des \u00e9tudes \u00e9conomiques (INSEE). Nomenclatures des professions et cat\u00e9gories socioprofessionnelles des emplois salari\u00e9s des employeurs priv\u00e9s et publics (PCS-ESE), https:\/\/www.insee.fr\/fr\/information\/2497958; 2018 Nov 16.[accessed 2025 Dec 19]."},{"key":"10.1016\/j.neurol.2026.01.267_bib0425","unstructured":"Direction de la recherche, des \u00e9tudes, de l\u2019\u00e9valuation et des statistiques (DREES). L\u2019\u00e9tat de sant\u00e9 de la population en France\u00a0: Rapport 2015, https:\/\/drees.solidarites-sante.gouv.fr\/sites\/default\/files\/2021-01\/rappeds_v11_16032015.pdf; 2015.[accessed 2025 Dec 19]."},{"key":"10.1016\/j.neurol.2026.01.267_bib0430","doi-asserted-by":"crossref","first-page":"362","DOI":"10.14283\/jpad.2023.30","article-title":"Lecanemab: appropriate use recommendations","volume":"10","author":"Cummings","year":"2023","journal-title":"J Prev Alzheimer's Dis"},{"key":"10.1016\/j.neurol.2026.01.267_bib0435","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1212\/WNL.0000000000013053","article-title":"Decisions with patients and families regarding aducanumab in Alzheimer disease, with recommendations for consent","volume":"98","author":"Chiong","year":"2022","journal-title":"Neurology"},{"key":"10.1016\/j.neurol.2026.01.267_bib0440","doi-asserted-by":"crossref","first-page":"8162","DOI":"10.1002\/alz.14199","article-title":"Benefits and risks of FDA-approved amyloid-targeting antibodies for treatment of early Alzheimer's disease: navigating clinician-patient engagement","volume":"20","author":"Rentz","year":"2024","journal-title":"Alzheimer Dement"},{"key":"10.1016\/j.neurol.2026.01.267_bib0445","doi-asserted-by":"crossref","first-page":"e215","DOI":"10.3346\/jkms.2025.40.e215","article-title":"Practical guide of the Korean Association for geriatric psychiatry to anti-amyloid monoclonal antibody therapy for Alzheimer's disease: focused on lecanemab","volume":"40","author":"Jeon","year":"2024","journal-title":"J Korean Med Sci"},{"key":"10.1016\/j.neurol.2026.01.267_bib0450","doi-asserted-by":"crossref","first-page":"246","DOI":"10.7326\/M23-3377","article-title":"Talking with patients about the new anti-amyloid Alzheimer disease medications","volume":"177","author":"Sarkisian","year":"2024","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.neurol.2026.01.267_bib0455","doi-asserted-by":"crossref","first-page":"100150","DOI":"10.1016\/j.tjpad.2025.100150","article-title":"Donanemab: appropriate use recommendations","volume":"12","author":"Rabinovici","year":"2025","journal-title":"J Prev Alzheimer Dis"},{"key":"10.1016\/j.neurol.2026.01.267_bib0460","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1177\/13872877251329519","article-title":"A qualitative study of people with Alzheimer's disease in a memory clinic considering lecanemab treatment","volume":"105","author":"Parks","year":"2025","journal-title":"J Alzheimer's Dis"},{"key":"10.1016\/j.neurol.2026.01.267_bib0465","doi-asserted-by":"crossref","first-page":"e70150","DOI":"10.1002\/trc2.70150","article-title":"Characterizing clinician communication with patients about lecanemab: a qualitative study of clinicians across seven academic medical centers","volume":"11","author":"Parks","year":"2025","journal-title":"Alzheimer's Dement Transl Res Clin Interv"},{"key":"10.1016\/j.neurol.2026.01.267_bib0470","series-title":"Medical decision-making capacity in patients with mild cognitive impairment","author":"Okonkwo","year":"2007"},{"key":"10.1016\/j.neurol.2026.01.267_bib0475","doi-asserted-by":"crossref","first-page":"1474","DOI":"10.1212\/01.wnl.0000334301.32358.48","article-title":"Medical decision-making capacity in mild cognitive impairment: a 3-year longitudinal study","volume":"71","author":"Okonkwo","year":"2008","journal-title":"Neurology"},{"issue":"3","key":"10.1016\/j.neurol.2026.01.267_bib0480","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1176\/ajp.134.3.279","article-title":"Tests of competency to consent to treatment","volume":"134","author":"Roth","year":"1977","journal-title":"Am J Psychiatry"},{"issue":"25","key":"10.1016\/j.neurol.2026.01.267_bib0485","doi-asserted-by":"crossref","first-page":"1635","DOI":"10.1056\/NEJM198812223192504","article-title":"Assessing patients\u2019 capacities to consent to treatment","volume":"319","author":"Appelbaum","year":"1988","journal-title":"N Engl J Med"},{"issue":"18","key":"10.1016\/j.neurol.2026.01.267_bib0490","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1056\/NEJMcp074045","article-title":"Assessment of patients\u2019 competence to consent to treatment","volume":"357","author":"Appelbaum","year":"2007","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.neurol.2026.01.267_bib0495","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1080\/07317110802072140","article-title":"Assessment of capacity to consent to treatment: challenges, the \u201cACCT\u201d approach, future directions","volume":"31","author":"Moye","year":"2007","journal-title":"Clin Gerontol"},{"key":"10.1016\/j.neurol.2026.01.267_bib0500","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1212\/WNL.0b013e318245f447","article-title":"Biomarker validation of a cued recall memory deficit in prodromal Alzheimer disease","volume":"78","author":"Wagner","year":"2012","journal-title":"Neurology"},{"issue":"8","key":"10.1016\/j.neurol.2026.01.267_bib0505","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1016\/j.cpr.2005.04.013","article-title":"Empirical advances in the assessment of the capacity to consent to medical treatment: clinical implications and research needs","volume":"26","author":"Moye","year":"2006","journal-title":"Clin Psychol Rev"},{"issue":"17\u201318","key":"10.1016\/j.neurol.2026.01.267_bib0510","doi-asserted-by":"crossref","first-page":"2387","DOI":"10.1111\/jocn.12215","article-title":"Assessing patient capacity to consent to treatment: an integrative review of instruments and tools","volume":"22","author":"Lamont","year":"2013","journal-title":"J Clin Nurs"},{"issue":"6","key":"10.1016\/j.neurol.2026.01.267_bib0515","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1093\/ageing\/afy096","article-title":"Tools for testing decision-making capacity in dementia","volume":"47","author":"Pennington","year":"2018","journal-title":"Age Ageing"},{"issue":"11","key":"10.1016\/j.neurol.2026.01.267_bib0520","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1176\/ps.48.11.1415","article-title":"The MacCAT-T: a clinical tool to assess patients\u2019 capacities to make treatment decisions","volume":"48","author":"Grisso","year":"1997","journal-title":"Psychiatr Serv"},{"issue":"1","key":"10.1016\/j.neurol.2026.01.267_bib0525","doi-asserted-by":"crossref","first-page":"e14204","DOI":"10.1002\/alz.14204","article-title":"Facing the new diagnostic and treatment options of Alzheimer's disease: the necessity of informed consent","volume":"21","author":"Karneboge","year":"2025","journal-title":"Alzheimers Dement"},{"key":"10.1016\/j.neurol.2026.01.267_bib0530","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1177\/153331750201700406","article-title":"Decision-making for persons with cognitive impairment and their family caregivers","volume":"17","author":"Feinberg","year":"2002","journal-title":"Am J Alzheimer's Dis Other Dement"},{"key":"10.1016\/j.neurol.2026.01.267_bib0535","doi-asserted-by":"crossref","first-page":"e70636","DOI":"10.1002\/alz.70636","article-title":"Supporting decision making for individuals living with dementia and their care partners with knowledge translation: an umbrella review","volume":"21","author":"Biard","year":"2025","journal-title":"Alzheimer's Dement"},{"key":"10.1016\/j.neurol.2026.01.267_bib0540","unstructured":"L\u00e9gifrance. Code de la Sant\u00e9 Publique, article L.\u00a01111-6, https:\/\/www.legifrance.gouv.fr\/codes\/article_lc\/LEGIARTI000036515020\/2020-08-31; 2024. [accessed 2025 Dec 19]."}],"container-title":["Revue Neurologique"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0035378726004467?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0035378726004467?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,14]],"date-time":"2026-04-14T08:50:20Z","timestamp":1776156620000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0035378726004467"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":54,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["S0035378726004467"],"URL":"https:\/\/doi.org\/10.1016\/j.neurol.2026.01.267","relation":{},"ISSN":["0035-3787"],"issn-type":[{"value":"0035-3787","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Simulated shared and supported decision making for amyloid immunotherapy in Alzheimer's disease: A bicentric study","name":"articletitle","label":"Article Title"},{"value":"Revue Neurologique","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.neurol.2026.01.267","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}]}}